InMed Pharma - INM Net earnings per share for the last four quarters

The volatility of InMed Pharmaceuticals (INM), which develops medical cannabinoids for cosmetology and pharmacy, is evident through the annual variability of TTM net income per share. Risks are mitigated by the synthesis of components for dermatology and ophthalmology, although the business relies solely on existing capital without active sales. The value of 54.60 expresses the metric's value today, capturing the company's current level of financial stability.
InMed Pharmaceuticals Inc. - analytical breakdowns and key metrics (INM)

InMed Pharmaceuticals (INM) maintains a strong position in the niche rare cannabinoid biosynthesis segment due to its patent protection. By analyzing the EPS YoY TTM growth, investors assess the dynamics of the rolling earnings per share. This indicator neutralizes discrepancies between GAAP and Non-GAAP standards, revealing the actual cash flow. For a company with early-stage medical programs, this pace reflects the scaling efficiency of the Integria technology. The market is currently pricing in the balance between current growth and the risk of capital volatility.